Telesis Bio Reports First Quarter 2023 Financial Results
May 11, 2023 16:05 ET
|
Telesis Bio
-- Total revenue of $6.3M in 1QFY23 -- BioXp® franchise revenue increased by 28% SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and...
Icosavax Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 10, 2023 16:05 ET
|
Icosavax, Inc.
- IVX-A12 (RSV+hMPV) Phase 1 topline interim data expected in 2Q 2023 - - Initiation of IVX-A12 Phase 2 trial expected in 2H 2023 - - Cash and cash equivalents, restricted cash, and short-term...
HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors
May 09, 2023 07:00 ET
|
HilleVax, Inc.
BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...
Recombinant proteins market is projected to grow at a CAGR of 11.14% by 2033: Visiongain Reports Ltd
May 05, 2023 11:43 ET
|
Visiongain Reports Ltd
Visiongain has published a new report: Recombinant Proteins Market: Forecasts by Products & Services (Cytokines & Growth Factors (Interferons (IFNs), Interleukins (ILS), Others), Antibodies,...
Uvax Bio Announces Publication of Results from Preclinical Studies of HIV Vaccine Candidates
April 26, 2023 07:30 ET
|
Uvax Bio
Uvax Bio-owned vaccines demonstrated significant improvement in immune response compared with current vaccine strategiesPhase 1 clinical trial sponsored by National Institutes of Health expected to...
HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate
April 25, 2023 06:45 ET
|
HilleVax, Inc.
Topline safety and clinical efficacy data from NEST-IN1 expected in the first quarter of 2024 HIL-214 is the most advanced vaccine candidate for norovirus infection There are currently no approved...
Recombinant proteins market is projected to grow at a CAGR of 11.14% by 2033: Visiongain Reports Ltd
April 20, 2023 11:52 ET
|
Visiongain Reports Ltd
Visiongain has published a new report: Recombinant Proteins Market:- Forecasts by Products & Services (Cytokines & Growth Factors (Interferons (IFNs), Interleukins (ILS), Others), Antibodies,...
Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform
April 18, 2023 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Guy De La Rosa, MD, Joins Curevo Vaccine as Chief Medical Officer
April 11, 2023 07:30 ET
|
Curevo Vaccine
SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe...
Icosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 30, 2023 16:05 ET
|
Icosavax, Inc.
- FDA granted Fast Track Designation for IVX-A12, a bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine candidate - - Completed dosing in ongoing Phase 1 study of...